News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Trump Does Not Rule Out Sending Troops to Iran; Iran Closes Strait of Hormuz, Oil Prices Soar; Drone and Space Stocks Rise Collectively (2026/03/03)2Bitcoin slide slowing, but bear market still in play: Analysts3Research Report｜In-Depth Analysis and Market Cap of Opinion Labs (OPN)
French Hill urges Senate to take up House crypto bill amid stablecoin yield fight
The Block·2026/03/03 21:45
Ethereum's Vitalik Buterin: build 'sanctuary tech,' forget emulating Apple or Google
The Block·2026/03/03 21:39
Anthropic's Tool Launch: A Strategic Boost for Technology Shares
101 finance·2026/03/03 21:27
A16z Crypto updates Jolt zkVM, challenges loose use of ‘ZK’ label
The Block·2026/03/03 21:15
Hasbro Relocates Headquarters: Savvy Financial Decision or Purposeful Organizational Shift?
101 finance·2026/03/03 21:03
Pi Network price prediction: $0.20 still in play as 3 signals align
AMBCrypto·2026/03/03 21:03
Mastercard and Visa strike agreements to boost stablecoins
101 finance·2026/03/03 21:00
Profit Realization and Guidance Adjustments: Navigating Expectation Gaps in Consumer Staples
101 finance·2026/03/03 20:57
XRP Under Pressure Despite 24 % Surge In Trading Volume
Cointribune·2026/03/03 20:57
38% of altcoins in critical zone according to CryptoQuant
Cointribune·2026/03/03 20:57
Flash
21:43
Vertiv (Vertiv Holdings LLC) recently announced the successful completion of two key financing transactions: a $2.1 billion senior unsecured bond issuance and a $2.5 billion senior unsecured revolving credit facility.This financing initiative significantly enhances the company's financial flexibility, providing solid capital support for future strategic planning and business expansion. By optimizing its capital structure, Vertiv further consolidates its market competitiveness in key areas of digital infrastructure.
21:43
The biopharmaceutical company Arbutus Biopharma Corporation (ABUS), a subsidiary of Roivant Sciences Ltd. (ROIV), is currently actively evaluating a capital return plan.The plan aims to return capital to the company's shareholders in the third quarter of the 2026 calendar year.
21:43
According to the settlement agreement, Genevant Sciences, a subsidiary of Roivant Sciences Ltd., will grant Moderna, Inc. a non-exclusive license allowing the use of its lipid nanoparticle delivery technology for applications in the field of infectious diseases.This arrangement resolves the intellectual property dispute between both parties.
News